Kestra Medical Technologies (NASDAQ:KMTS) Issues Quarterly Earnings Results

Kestra Medical Technologies (NASDAQ:KMTS) released its quarterly earnings results on Tuesday. The company reported ($0.61) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $24.55 million during the quarter.

Kestra Medical Technologies Price Performance

KMTS stock traded up $1.88 during midday trading on Tuesday, reaching $21.14. The company had a trading volume of 475,200 shares, compared to its average volume of 292,819. Kestra Medical Technologies has a 1-year low of $13.25 and a 1-year high of $30.00. The stock has a 50 day moving average price of $24.42 and a 200-day moving average price of $24.53. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47. The company has a market capitalization of $1.23 billion and a price-to-earnings ratio of -6.67.

Wall Street Analyst Weigh In

KMTS has been the subject of a number of research reports. Piper Sandler lifted their target price on Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. BTIG Research started coverage on shares of Kestra Medical Technologies in a research report on Tuesday, November 18th. They set a “buy” rating and a $32.00 price target on the stock. Wells Fargo & Company boosted their price objective on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, December 12th. The Goldman Sachs Group set a $24.00 target price on shares of Kestra Medical Technologies in a report on Friday, January 16th. Finally, Stifel Nicolaus set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

Insider Activity

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $25.60, for a total transaction of $384,000.00. Following the sale, the insider owned 379,786 shares in the company, valued at approximately $9,722,521.60. This trade represents a 3.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Traci S. Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the completion of the transaction, the insider directly owned 136,633 shares in the company, valued at $3,646,734.77. This trade represents a 7.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 55,500 shares of company stock worth $1,405,095. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently modified their holdings of KMTS. Invesco Ltd. acquired a new position in shares of Kestra Medical Technologies during the 4th quarter worth $239,000. Perceptive Advisors LLC bought a new position in Kestra Medical Technologies in the fourth quarter valued at about $7,558,000. Janus Henderson Group PLC bought a new position in Kestra Medical Technologies in the fourth quarter valued at about $300,000. Balyasny Asset Management L.P. raised its stake in Kestra Medical Technologies by 80.6% during the fourth quarter. Balyasny Asset Management L.P. now owns 6,915 shares of the company’s stock worth $183,000 after acquiring an additional 3,086 shares in the last quarter. Finally, Burkehill Global Management LP bought a new position in shares of Kestra Medical Technologies in the fourth quarter worth about $1,326,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.